Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) registered its phase 2 clinical trial application for its Xiao Chaihu granules for children, according to a Tuesday filing with the Shanghai bourse.
The drug is indicated for gastrointestinal colds or stomach flu with Shaoyang syndrome in children, the filing said.
Shares fell 1% in Hong Kong and Shanghai during late morning trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.